170 related articles for article (PubMed ID: 16838449)
1. Fraud, errors taint a key study of widely used Sanofi drug; despite some faked results, FDA approves antibiotic; one doctor's cocaine use; company defends safety.
Mathews AW
Wall St J (East Ed); 2006 May; ():A1, A12. PubMed ID: 16838449
[No Abstract] [Full Text] [Related]
2. The FDA and the case of Ketek.
Ross DB
N Engl J Med; 2007 Apr; 356(16):1601-4. PubMed ID: 17442902
[No Abstract] [Full Text] [Related]
3. Ketek--the FDA perspective.
Soreth J; Cox E; Kweder S; Jenkins J; Galson S
N Engl J Med; 2007 Apr; 356(16):1675-6. PubMed ID: 17442912
[No Abstract] [Full Text] [Related]
4. A fine pile of paté: the cautionary tale of telithromycin, hepatic failure, and study 3014.
Barie PS
Surg Infect (Larchmt); 2006 Jun; 7(3):247-9. PubMed ID: 16875457
[No Abstract] [Full Text] [Related]
5. A doctor's drug studies turn into fraud.
Eichenwald K; Kolata G
N Y Times Web; 1999 May; ():A1, A16. PubMed ID: 11647660
[No Abstract] [Full Text] [Related]
6. FDA under pressure to relax drug rules.
Ledford H
Nature; 2012 Dec; 492(7427):19. PubMed ID: 23222585
[No Abstract] [Full Text] [Related]
7. The role of data audits in detecting scientific misconduct. Results of the FDA program.
Shapiro MF; Charrow RP
JAMA; 1989 May; 261(17):2505-11. PubMed ID: 2704109
[TBL] [Abstract][Full Text] [Related]
8. Panel faults Pfizer in '96 clinical trial in Nigeria.
Stephens J
Washington Post; 2006 May; ():A1, A21. PubMed ID: 16718960
[No Abstract] [Full Text] [Related]
9. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world.
Echols RM
Ann N Y Acad Sci; 2011 Dec; 1241():153-61. PubMed ID: 22191531
[TBL] [Abstract][Full Text] [Related]
10. Telithromycin and acute liver failure.
Graham DJ
N Engl J Med; 2006 Nov; 355(21):2260-1. PubMed ID: 17124030
[No Abstract] [Full Text] [Related]
11. Data audit by a regulatory agency: its effect and implication for others.
Shapiro MF
Account Res; 1992; 2(3):219-29. PubMed ID: 11653981
[No Abstract] [Full Text] [Related]
12. Telithromycin and the FDA: implications for the future.
Shlaes DM; Moellering RC
Lancet Infect Dis; 2008 Feb; 8(2):83-5. PubMed ID: 18222155
[No Abstract] [Full Text] [Related]
13. Effective integration of medical and pharmacy claims to better protect patient safety--a long road yet to travel.
Curtiss FR
J Manag Care Pharm; 2007 Jun; 13(5):429-30. PubMed ID: 17605515
[No Abstract] [Full Text] [Related]
14. Innovation and integrity in biomedical research.
Jasanoff S
Acad Med; 1993 Sep; 69(9 Suppl):S91-5. PubMed ID: 11652808
[No Abstract] [Full Text] [Related]
15. Scientific misconduct in investigational drug trials.
Shapiro MF; Charrow RP
N Engl J Med; 1985 Mar; 312(11):731-6. PubMed ID: 3974649
[No Abstract] [Full Text] [Related]
16. More Halcion headaches.
Cowley G
Newsweek; 1994 Mar; 123(10):50-2. PubMed ID: 11652702
[No Abstract] [Full Text] [Related]
17. Scientific misconduct: a form of white coat crime.
Kline S
J Pharm Law; 1993; 2(1):15-34. PubMed ID: 11653114
[No Abstract] [Full Text] [Related]
18. Drug makers relied on clinical researchers who now await trial.
Stecklow S; Johannes L
Wall St J (East Ed); 1997 Aug; ():A1, A6. PubMed ID: 11647688
[No Abstract] [Full Text] [Related]
19. New safety information on Ketek.
FDA Consum; 2006; 40(5):8. PubMed ID: 17328103
[No Abstract] [Full Text] [Related]
20. Shared responsibility in clinical research.
Nightingale SL
Circulation; 1985 Aug; 72(2 Pt 2):I25-30. PubMed ID: 3891137
[No Abstract] [Full Text] [Related]
[Next] [New Search]
